ARCHIVES

Phase III Xilonix Study Halted Following Unscheduled Analysis

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

How a two-faced media covered cancer: Promoting research—and cigarettes

April 29, 2022

Two Regorafenib Trials Demonstrate Efficacy, Improve Overall and Progression-Free Survival

December 28, 2012

Pittsburgh Reprimands Staff For Use of Univ. Resources In Mailing

May 13, 1994

Health Reform Plans Offer Difficult Choices For Patients, Researchers, Practitioners

February 25, 1994

Crout Resigns As Director Of FDA Drugs Bureau

July 11, 1980

Cancer Meetings Listed

March 26, 1993